Active CLL with Unmutated IGHV Status in Medically Unfit Patients (Without TP53 Mutation or del(17p))
Clinical Scenario
This protocol addresses active chronic lymphocytic leukemia presenting with unmutated IGHV status, in patients who lack both a TP53 mutation and del(17p), and who are not medically fit due to significant comorbidity.
Defining Patient Profile
The key features that distinguish this scenario are active CLL, unmutated IGHV, absence of TP53 mutation and del(17p) abnormality, and medical unfitness arising from significant underlying comorbidity. This combination of findings drives a specific therapeutic pathway distinct from fit patients or those with high-risk genomic alterations.
Treatment Approach — Partial Overview
For eligible patients in this scenario, advanced cellular therapy strategies are among the options to be considered. In addition, participation in clinical trials exploring newer immunotherapeutic modalities may represent a further pathway for appropriate patients. The complete evidence-based regimen, including all applicable options and sequencing, is available via the full protocol.
References
- CLL with unmutated IGHV status and without TP53 mutation or del(17p) (if there was similar efficacy, panel is giving preference to time-limited therapies): Unfit patients: venetoclax plus obinutuzumab or ibrutinib or acalabrutinib [I, A] or chlorambucil plus obinutuzumab.
- Allogeneic stem cell transplantation (alloSCT) should be considered in: Patients refractory to CIT and to novel inhibitor therapy, even for patients with a higher risk of non-relapse mortality [haematopoietic cell transplant comorbidity index (HCT-CI) score of 3] [III, B].
- Treatment with chimeric antigen receptor T (CAR-T) cells or bi-specific T-cell engager (BiTE) antibodies within clinical trials could be an alternative to alloSCT for all three groups [V, B].
View source ↗